Ensysce Biosciences (ENSC) Cash from Investing Activities (2018 - 2022)
Ensysce Biosciences (ENSC) posted quarterly Cash from Investing Activities of $4500.0 for Q1 2022, up 107.2% year-over-year from $2171.8 in Q1 2021, and up 107.2% quarter-over-quarter from -$62500.0 in Q1 2021.
Ensysce Biosciences (ENSC) Cash from Investing Activities (2018 - 2022) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Cash from Investing Activities for 5 consecutive years, with $4500.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Cash from Investing Activities rose 107.2% year-over-year to $4500.0; the TTM figure through Dec 2022 stood at $4500.0 (changed N/A YoY), while the FY2022 annual figure was $4500.0, changed N/A from the prior year.
- Cash from Investing Activities advanced to $4500.0 in Q1 2022 per ENSC's latest filing, from -$62500.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $183.4 million in Q4 2020 and bottomed at -$182.8 million in Q3 2020.
- Historically, Cash from Investing Activities has averaged $14.0 million across 5 years, with a median of $211519.0 in 2018.
- On a YoY basis, Cash from Investing Activities climbed as much as 88935.13% in 2020 and fell as far as 127049.76% in 2020.
- Ensysce Biosciences' Cash from Investing Activities stood at $362773.0 in 2018, then soared by 2995.65% to $11.2 million in 2019, then soared by 1533.16% to $183.4 million in 2020, then slumped by 100.03% to -$62500.0 in 2021, then soared by 107.2% to $4500.0 in 2022.
- Business Quant data shows ENSC's Cash from Investing Activities at $4500.0 in Q1 2022, -$62500.0 in Q1 2021, and $183.4 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 4,500.00 |
| Mar 31, 2022 | 4,500.00 |
| Mar 31, 2021 | -62,500.00 |
| Mar 31, 2021 | -62,500.00 |
| Dec 31, 2020 | 183.41 Mn |
| Dec 31, 2020 | 183.41 Mn |
| Sep 30, 2020 | -182.81 Mn |
| Sep 30, 2020 | -182.81 Mn |
| Jun 30, 2020 | 48.18 Mn |
| Jun 30, 2020 | 48.18 Mn |
| Mar 31, 2020 | 134.62 Mn |
| Mar 31, 2020 | 134.62 Mn |
| Dec 31, 2019 | 11.23 Mn |
| Dec 31, 2019 | 11.23 Mn |
| Sep 30, 2019 | 144,000.00 |
| Sep 30, 2019 | 144,000.00 |
| Jun 30, 2019 | 328,000.00 |
| Jun 30, 2019 | 328,000.00 |
| Mar 31, 2019 | 151,204.00 |
| Mar 31, 2019 | 151,204.00 |